What is Fauna Bio?
Fauna Bio operates at the vanguard of biotechnology, specializing in the analysis of animal genomics to unlock novel pathways for human health. By studying the unique physiological adaptations of various species, the company identifies genetic markers that can be translated into effective therapies for complex human diseases. This comparative genomics approach positions Fauna Bio as a critical player in the modern drug development ecosystem, offering a data-driven alternative to conventional research methodologies. The firm's focus on high-throughput genomic screening and computational biology allows it to accelerate the identification of therapeutic targets, effectively bridging the gap between evolutionary biology and clinical application.
How much funding has Fauna Bio raised?
Fauna Bio has raised a total of $13.1M across 2 funding rounds:
Angel/Seed
$4.1M
Angel/Seed
$9M
Angel/Seed (2019): $4.1M, investors not publicly disclosed
Angel/Seed (2021): $9M led by True Ventures, Lifeforce Capital Gp I, and Boom Capital
Key Investors in Fauna Bio
True Ventures
A venture capital firm focused on early-stage technology startups, providing mentorship and capital to founders building transformative companies.
Lifeforce Capital Gp I
Lifeforce Capital is a venture capital firm. It focuses on identifying and scaling software-driven companies in healthcare. The company was established in 2015.
Boom Capital
An investment firm that supports high-growth ventures, often providing the necessary resources for companies to scale their innovative research and development efforts.
What's next for Fauna Bio?
With this latest capital infusion, Fauna Bio is well-positioned to scale its research operations and expand its therapeutic pipeline. The company is expected to prioritize the validation of its lead candidates while further enhancing its computational infrastructure to handle increasingly complex genomic datasets. As the firm transitions into a more mature phase of development, the focus will likely shift toward strategic partnerships with pharmaceutical entities and the advancement of its most promising programs into preclinical trials. This phase of growth will be critical in demonstrating the scalability of its genomic insights and securing its long-term competitive advantage in the global biotech market.
See full Fauna Bio company page
